WCG targets pain management, opioid alternatives in Analgesic Solutions deal

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/gradyreese)
(Image: Getty/gradyreese)

Related tags: WCG, Opioid, Opioid epidemic, Clinical trials, Fda, acquistion

WCG acquires Analgesic Solutions for advisement on protocol design and the development of clinical trials in which pain is an indicator of an underlying condition.

The WIRB-Copernicus Group (WCG) Clinical Services Division acquired pain medications developer Analgesic Solutions to strengthen clinical trial processes and advance alternatives to opioids which are in great demand.

Robert Newman, CEO of Analgesic Solutions, said in a statement, “The quest to combat the misuse and abuse of pharmaceuticals and to uncover effective pain management alternatives has brought many new players to the space.”

However, trials for pain management alternatives have unique challenges that make the studies difficult to conduct, he explained.

According to Analgesic Solutions, because pain is a subjective experience, the company advises clinicians on how to better evaluate patients’ descriptions in clinical trials in which pain is an endpoint or significant component.

Analgesic Solutions will advise sponsors on protocol design and development, providing central statistical monitoring to proactively ensure accurate study outcomes. Analgesic Solutions also works with companies for submissions to the US Food and Drug Administration (FDA) and other regulatory organizations.

Per the acquisition, WCG gains access to Analgesic Solutions’ Misuse, Abuse, and Diversion Drug Event Reporting System (MADDERS), created in collaboration with the FDA-ACTTION​ initiative, for classifying and quantifying abuse-related events in clinical trials. The acquisition will see Analgesic Solutions gain access to capital, expertise and corporate operational support. The company will continue to operate independently at its headquarters in Wayland, MA. 

Related news

Related products

show more

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars